Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean.
Latest Information Update: 08 Nov 2021
Price :
$35 *
At a glance
- Drugs Sunitinib (Primary) ; Bevacizumab; Interferon alpha
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 21 Sep 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Aug 2011 Actual end date (February 2011) added as reported by ClinicalTrials.gov.
- 22 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.